Abbott Laboratories' (NYSE:ABT) Business Is Yet to Catch Up With Its Share Price




  • In Business
  • 2022-12-04 14:00:17Z
  • By Simply Wall St.
 

With a price-to-earnings (or "P/E") ratio of 24x Abbott Laboratories (NYSE:ABT) may be sending very bearish signals at the moment, given that almost half of all companies in the United States have P/E ratios under 14x and even P/E's lower than 8x are not unusual. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.

Recent earnings growth for Abbott Laboratories has been in line with the market. One possibility is that the P/E is high because investors think this modest earnings performance will accelerate. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.

See our latest analysis for Abbott Laboratories

Want the full picture on analyst estimates for the company? Then our free report on Abbott Laboratories will help you uncover what's on the horizon.

Is There Enough Growth For Abbott Laboratories?

In order to justify its P/E ratio, Abbott Laboratories would need to produce outstanding growth well in excess of the market.

If we review the last year of earnings growth, the company posted a worthy increase of 10%. Pleasingly, EPS has also lifted 143% in aggregate from three years ago, partly thanks to the last 12 months of growth. Therefore, it's fair to say the earnings growth recently has been superb for the company.

Shifting to the future, estimates from the analysts covering the company suggest earnings growth is heading into negative territory, declining 1.6% each year over the next three years. With the market predicted to deliver 9.1% growth each year, that's a disappointing outcome.

In light of this, it's alarming that Abbott Laboratories' P/E sits above the majority of other companies. Apparently many investors in the company reject the analyst cohort's pessimism and aren't willing to let go of their stock at any price. Only the boldest would assume these prices are sustainable as these declining earnings are likely to weigh heavily on the share price eventually.

The Bottom Line On Abbott Laboratories' P/E

We'd say the price-to-earnings ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

Our examination of Abbott Laboratories' analyst forecasts revealed that its outlook for shrinking earnings isn't impacting its high P/E anywhere near as much as we would have predicted. When we see a poor outlook with earnings heading backwards, we suspect the share price is at risk of declining, sending the high P/E lower. This places shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.

It is also worth noting that we have found 1 warning sign for Abbott Laboratories that you need to take into consideration.

Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with a strong growth track record, trading on a P/E below 20x.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You'll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

COMMENTS

More Related News

Sanofi forecasts moderate profit growth on Dupixent demand
Sanofi forecasts moderate profit growth on Dupixent demand
  • US
  • 2023-02-03 06:54:21Z

(Reuters) -Sanofi forecast moderate earnings growth that undershot expectations, saying demand for bestselling asthma and eczema drug Dupixent would be...

Should Weakness in Alphawave IP Group plc
Should Weakness in Alphawave IP Group plc's (LON:AWE) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

With its stock down 15% over the past month, it is easy to disregard Alphawave IP Group (LON:AWE). But if you pay close...

Lacklustre Performance Is Driving Negri Sembilan Oil Palms Berhad
Lacklustre Performance Is Driving Negri Sembilan Oil Palms Berhad's (KLSE:NSOP) Low P/E

When close to half the companies in Malaysia have price-to-earnings ratios (or "P/E's") above 14x, you may consider...

Irish Continental Group plc
Irish Continental Group plc's (LON:ICGC) Has Performed Well But Fundamentals Look Varied: Is There A Clear Direction For The Stock?

Irish Continental Group's (LON:ICGC) stock is up by 8.4% over the past three months. Given that the stock prices...

Why Investors Shouldn
Why Investors Shouldn't Be Surprised By Bermaz Auto Berhad's (KLSE:BAUTO) Low P/E

When close to half the companies in Malaysia have price-to-earnings ratios (or "P/E's") above 14x, you may consider...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business